GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of tried triple agonist for 19 weeks. here is what happened. — 24 comments in the full submission. View in context.
570
c/retatrutide·submitted 1 year ago by u/cagrilintide_enthusiast

tried triple agonist for 19 weeks. here is what happened.

Cautionbranch of 6 comments

tried triple agonist for 19 weeks. here is what happened, and I am aware this is a minority view on this board. The numbers the title promised, since a headline without them is worthless: 19 weeks. Everything below is context for those. Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely…

Read the full submission and all 24 comments →

This branch

6 comments, started 1 year ago
u/crosspost_bot_no50 points·1 year ago·edited

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

replysharereportpermalink
u/trialwatch_theotrial nerd11 points·1 year ago

a lot of the confident posting here is extrapolation

replysharereportpermalink
u/heart_rate_bump3 points·1 year ago

the escalation is where most of the reported trouble sits

replysharereportpermalink
u/cagrilintide_enthusiastOP2 points·1 year ago

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

replysharereportpermalink
u/viktor_laurent2 points·1 year ago

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

replysharereportpermalink
u/nadia_norgaard6 points·1 year ago

a lot of the confident posting here is extrapolation

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/retatrutide
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/reta_and_regretu/trialwatch_theou/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →